Navana Pharmaceuticals PLC (DSE:NAVANAPHAR)
Bangladesh · Delayed Price · Currency is BDT 52.90
-0.50 (-0.94%)
At close: Jan 22, 2026
Navana Pharmaceuticals Revenue
Navana Pharmaceuticals had revenue of 2.81B BDT in the quarter ending September 30, 2025, with 31.69% growth. This brings the company's revenue in the last twelve months to 9.52B, up 28.58% year-over-year. In the fiscal year ending June 30, 2025, Navana Pharmaceuticals had annual revenue of 8.84B with 28.19% growth.
Revenue (ttm)
9.52B
Revenue Growth
+28.58%
P/S Ratio
0.60
Revenue / Employee
1.98M
Employees
4,798
Market Cap
5.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 8.84B | 1.94B | 28.19% |
| Jun 30, 2024 | 6.90B | 1.19B | 20.89% |
| Jun 30, 2023 | 5.71B | 947.45M | 19.91% |
| Jun 30, 2022 | 4.76B | 1.15B | 31.95% |
| Jun 30, 2021 | 3.61B | 457.57M | 14.53% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| The ACME Laboratories | 37.48B |
| The IBN SINA Pharmaceutical Industry | 12.84B |
| Techno Drugs | 3.23B |
| Orion Pharma | 3.23B |
| Asiatic Laboratories | 2.24B |
| Pharma Aids | 453.49M |
| Silco Pharmaceuticals | 428.63M |
| Silva Pharmaceuticals | 370.96M |